Saturday 17 October 2026
Export ZURA’s income statement to Excel — free account
Zura Bio Limited
ZURA Healthcare Biotechnology
In the quarter to June 2026, EPS fell 23.5% and free cash flow fell 30.4%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.88
0.40
−9.35%
Follow ZURA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | — | — | 3.91 | 2.00 | 0.97 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | — | — | 37.55 | 6.35 | 5.62 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | — | — | — | 15 | 30 | 40 | ||||
| Revenue/emp, $m | — | — | — | — | — | — | — | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | — | — | — | — | — | — | — | |||||
| EBT | — | — | — | — | — | 7 | (27) | (61) | (52) | (69) | |||||
| EBT margin, % | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | — | — | 7 | (27) | (61) | (52) | (69) | |||||
| Depreciation | — | — | — | — | — | — | — | — | 0 | 0 | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | — | — | 2.19 | (119.88) | (2.09) | (0.60) | (1.06) | |||||
| Cash flow | — | — | — | — | — | (0.35) | (5.27) | (0.46) | (0.37) | (0.69) | |||||
| Capex | — | — | — | — | — | 0.00 | (52.63) | (0.24) | (0.07) | 0.00 | |||||
| Free cash flow | — | — | — | — | — | (0.35) | (57.90) | (0.70) | (0.44) | (0.69) | |||||
| Book value | — | — | — | — | — | (2.93) | (41.91) | 1.84 | 1.98 | 1.08 | |||||
| Shares, m | — | — | — | — | — | 3 | 0 | 33 | 75 | 94 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | — | — | (1) | (1) | (15) | (28) | (65) | ||||
| Capex | — | — | — | — | — | — | (12) | (8) | (5) | 0 | |||||
| Free cash flow | — | — | — | — | — | (1) | (13) | (23) | (33) | (65) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | — | — | 1 | (13) | 81 | 159 | 100 | ||||
| Total debt | — | — | — | — | — | — | 0 | — | — | — | |||||
| Net debt | — | — | — | — | — | (1) | (2) | (100) | (176) | (109) | |||||
| Shareholders’ equity | — | — | — | — | — | (9) | (10) | 61 | 148 | 102 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | — | — | 4.87 | (44.43) | (130.52) | (32.38) | (67.71) | ||||
| ROIC | — | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | — | — | 11.32 | 207.38 | (356.78) | (43.38) | (79.52) | |||||
Negative figures in brackets.
Charts ten years each
Zura Bio Limited vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| INDP Indaptus Therapeutics, Inc. | $437.7M | — (loss-making) | — | — | n/m | +52.03% (above 0%: growing) | 0.00% | 0.00% | Compare |
| PRTA Prothena Corporation plc | $436.4M | — (loss-making) | 188× | −77.15% (below 0%: shrinking) | n/m | +44.64% (above 0%: growing) | 100.00% | (2,089.21%) | Compare |
| DMAC DiaMedica Therapeutics, Inc. | $433.6M | — (loss-making) | — (loss-making) | — | n/m | −6.75% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PRTCY PureTech Health PLC Sponsored ADR | $424.0M | — (loss-making) | — (loss-making) | −44.60% (below 0%: shrinking) | +66.43% (above 0%: growing) | +19.27% (above 0%: growing) | 2.83% | 0.00% | Compare |
| CAPR Capricor Therapeutics, Inc. | $422.7M | — (loss-making) | — (loss-making) | −7.92% (below 0%: shrinking) | n/m | −72.88% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| ASMB Assembly Biosciences, Inc. | $418.8M | 19.7× | — (loss-making) | +38.94% (above 0%: growing) | n/m | +7.58% (above 0%: growing) | 100.00% | (47.44%) | Compare |
| TECX Tectonic Therapeutic, Inc. | $416.4M | — (loss-making) | — | — | n/m | −46.69% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| ZURA Zura Bio Limited | $410.2M | — (loss-making) | — | — | n/m | −30.41% (below 0%: shrinking) | — | 0.00% | |
| SPRY ARS Pharmaceuticals, Inc. | $404.8M | — (loss-making) | — (loss-making) | +114.15% (above 0%: growing) | n/m | −53.69% (below 0%: shrinking) | 61.83% | (182.62%) | Compare |
| Median of peers | $423.3M | — | — | −7.92% | — | +0.42% | 32.33% | 0.00% |
Zura Bio Limited (ZURA) key facts
- Zura Bio Limited (ZURA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, ZURA traded at $3.88, a market capitalization of $410.2 million.
- Return on equity was −79.5% and debt-to-equity 0.00.
Zura Bio Limited (ZURA) Latest News
No news at this impact. Lower the threshold for more.